Search Results - (Author, Cooperation:N. Mulder)
-
1Latest Papers from Table of Contents or Articles in PressC. Rotimi ; A. Abayomi ; A. Abimiku ; V. M. Adabayeri ; C. Adebamowo ; E. Adebiyi ; A. D. Ademola ; A. Adeyemo ; D. Adu ; D. Affolabi ; G. Agongo ; S. Ajayi ; S. Akarolo-Anthony ; R. Akinyemi ; A. Akpalu ; M. Alberts ; O. Alonso Betancourt ; A. M. Alzohairy ; G. Ameni ; O. Amodu ; G. Anabwani ; K. Andersen ; F. Arogundade ; O. Arulogun ; D. Asogun ; R. Bakare ; N. Balde ; M. L. Baniecki ; C. Beiswanger ; A. Benkahla ; L. Bethke ; M. Boehnke ; V. Boima ; J. Brandful ; A. I. Brooks ; F. C. Brosius ; C. Brown ; B. Bucheton ; D. T. Burke ; B. G. Burnett ; S. Carrington-Lawrence ; N. Carstens ; J. Chisi ; A. Christoffels ; R. Cooper ; H. Cordell ; N. Crowther ; T. Croxton ; J. de Vries ; L. Derr ; P. Donkor ; S. Doumbia ; A. Duncanson ; I. Ekem ; A. El Sayed ; M. E. Engel ; J. C. Enyaru ; D. Everett ; F. M. Fadlelmola ; E. Fakunle ; K. H. Fischbeck ; A. Fischer ; O. Folarin ; J. Gamieldien ; R. F. Garry ; S. Gaseitsiwe ; R. Gbadegesin ; A. Ghansah ; M. Giovanni ; P. Goesbeck ; F. X. Gomez-Olive ; D. S. Grant ; R. Grewal ; M. Guyer ; N. A. Hanchard ; C. T. Happi ; S. Hazelhurst ; B. J. Hennig ; C. Hertz ; Fowler ; W. Hide ; F. Hilderbrandt ; C. Hugo-Hamman ; M. E. Ibrahim ; R. James ; Y. Jaufeerally-Fakim ; C. Jenkins ; U. Jentsch ; P. P. Jiang ; M. Joloba ; V. Jongeneel ; F. Joubert ; M. Kader ; K. Kahn ; P. Kaleebu ; S. H. Kapiga ; S. K. Kassim ; I. Kasvosve ; J. Kayondo ; B. Keavney ; A. Kekitiinwa ; S. H. Khan ; P. Kimmel ; M. C. King ; R. Kleta ; M. Koffi ; J. Kopp ; M. Kretzler ; J. Kumuthini ; S. Kyobe ; C. Kyobutungi ; D. T. Lackland ; K. A. Lacourciere ; G. Landoure ; R. Lawlor ; T. Lehner ; M. Lesosky ; N. Levitt ; K. Littler ; Z. Lombard ; J. F. Loring ; S. Lyantagaye ; A. Macleod ; E. B. Madden ; C. R. Mahomva ; J. Makani ; M. Mamven ; M. Marape ; G. Mardon ; P. Marshall ; D. P. Martin ; D. Masiga ; R. Mason ; M. Mate-Kole ; E. Matovu ; M. Mayige ; B. M. Mayosi ; J. C. Mbanya ; S. A. McCurdy ; M. I. McCarthy ; H. McIlleron ; S. O. Mc'Ligeyo ; C. Merle ; A. O. Mocumbi ; C. Mondo ; J. V. Moran ; A. Motala ; M. Moxey-Mims ; W. S. Mpoloka ; C. L. Msefula ; T. Mthiyane ; N. Mulder ; G. Mulugeta ; D. Mumba ; J. Musuku ; M. Nagdee ; O. Nash ; D. Ndiaye ; A. Q. Nguyen ; M. Nicol ; O. Nkomazana ; S. Norris ; B. Nsangi ; A. Nyarko ; M. Nyirenda ; E. Obe ; R. Obiakor ; A. Oduro ; S. F. Ofori-Acquah ; O. Ogah ; S. Ogendo ; K. Ohene-Frempong ; A. Ojo ; T. Olanrewaju ; J. Oli ; C. Osafo ; O. Ouwe Missi Oukem-Boyer ; B. Ovbiagele ; A. Owen ; M. O. Owolabi ; L. Owolabi ; E. Owusu-Dabo ; G. Pare ; R. Parekh ; H. G. Patterton ; M. B. Penno ; J. Peterson ; R. Pieper ; J. Plange-Rhule ; M. Pollak ; J. Puzak ; R. S. Ramesar ; M. Ramsay ; R. Rasooly ; S. Reddy ; P. C. Sabeti ; K. Sagoe ; T. Salako ; O. Samassekou ; M. S. Sandhu ; O. Sankoh ; F. S. Sarfo ; M. Sarr ; G. Shaboodien ; I. Sidibe ; G. Simo ; M. Simuunza ; L. Smeeth ; E. Sobngwi ; H. Soodyall ; H. Sorgho ; O. Sow Bah ; S. Srinivasan ; D. J. Stein ; E. S. Susser ; C. Swanepoel ; G. Tangwa ; A. Tareila ; O. Tastan Bishop ; B. Tayo ; N. Tiffin ; H. Tinto ; E. Tobin ; S. M. Tollman ; M. Traore ; M. J. Treadwell ; J. Troyer ; M. Tsimako-Johnstone ; V. Tukei ; I. Ulasi ; N. Ulenga ; B. van Rooyen ; A. P. Wachinou ; S. P. Waddy ; A. Wade ; M. Wayengera ; J. Whitworth ; L. Wideroff ; C. A. Winkler ; S. Winnicki ; A. Wonkam ; M. Yewondwos ; T. sen ; N. Yozwiak ; H. Zar
American Association for the Advancement of Science (AAAS)
Published 2014Staff ViewPublication Date: 2014-06-21Publisher: American Association for the Advancement of Science (AAAS)Print ISSN: 0036-8075Electronic ISSN: 1095-9203Topics: BiologyChemistry and PharmacologyComputer ScienceMedicineNatural Sciences in GeneralPhysicsKeywords: Africa ; Disease/*genetics ; England ; Genetics, Medical/trends ; Genome-Wide Association Study/*trends ; Genomics/*trends ; Health ; Humans ; National Institutes of Health (U.S.) ; United StatesPublished by: -
2Latest Papers from Table of Contents or Articles in PressStaff View
Publication Date: 2018-01-18Publisher: Royal SocietyElectronic ISSN: 2054-5703Topics: Natural Sciences in GeneralKeywords: computational biology, health and disease and epidemiologyPublished by: -
3Articles: DFG German National LicensesVAN ZANTEN, J. ; HOSPERS, G. A. P. ; HARMSEN, M. C. ; THE, T. H. ; MULDER, N. H. ; DE LEIJ, L. F. M. H.
Oxford, UK : Blackwell Science Ltd
Published 2002Staff ViewISSN: 1365-3083Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: We investigated if dendritic cells (DCs) were able to present intracellularly located antigens derived from apoptotic cells to T cells, thereby inducing a CD4+ and a CD8+ response. A transfected cell line with the cytomegalovirus-derived protein pp65 was triggered to go into apoptosis by ultraviolet B (UVB) irradiation, and after the uptake of apoptotic cells by DC, the activation and proliferation of T cells were determined. We found that DC efficiently phagocytosed apoptotic cells and induced a CD4+ and a CD8+ T-cell response specific for the viral protein pp65. This mechanism can be useful for vaccination studies to induce an antiviral immune response.Type of Medium: Electronic ResourceURL: -
4Articles: DFG German National LicensesStockhammer, G. ; Brotchi, J. ; Leblanc, R. ; Bernstein, M. ; Schackert, G. ; Weber, F. ; Ostertag, C. ; Mulder, N. H. ; Mellstedt, H. ; Seiler, R. ; Yonekawa, Y. ; Twerdy, K. ; Kostron, H. ; Witte, O. De ; Lambermont, M. ; Velu, T. ; Laneuville, P. ; Villemure, J.-G. ; Rutka, J. T. ; Warnke, P. ; Laseur, M. ; Mooij, J. J. A. ; Boëthius, J. ; Mariani, L. ; Meyer, M.
Springer
Published 1997Staff ViewISSN: 1432-1440Source: Springer Online Journal Archives 1860-2000Topics: MedicineType of Medium: Electronic ResourceURL: -
5Articles: DFG German National LicensesKroesen, B. J. ; Haar, A. ; Spakman, H. ; Willemse, P. ; Sleijfer, D. Th. ; Vries, E. G. E. ; Mulder, N. H. ; Berendsen, H. H. ; Limburg, P. C. ; The, T. H. ; Leij, L.
Springer
Published 1993Staff ViewISSN: 1432-0851Keywords: Immunotherapy ; Bispecific monoclonal antibodies ; T cell targeting ; Inflammation ; T cell activation ; CarcinomaSource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Abstract In a pilot clinical study carcinoma patients with malignant ascites or pleural exudates have been treated locally with autologous lymphocytes activated ex vivo and redirected towards tumour cells with bispecific monoclonal antibodies. BIS-1, the bispecific monoclonal antibody used in this study, combines specificity against a tumour-associated antigen, AMOC-31, present on carcinomas, with a specificity against the CD3 complex on T lymphocytes. Patients selected for treatment had malignant pleural or peritoneal effusions. Treatment consisted of isolating autologous peripheral blood lymphocytes, ex vivo activation, incubation with bispecific monoclonal antibodies and injection at the effusion site of these BIS-1-redirected lymphocytes. To evaluate the effects of the bispecific monoclonal antibody, five patients received treatments with activated lymphocytes without bispecific antibodies. Effusion samples taken before and at various times after treatment were analysed by immunocytology and for the presence of the soluble factors carcinoembryonic antigen (CEA), interleukin-6 (IL-6), tumour necrosis factor (TNF), C-reactive protein and soluble CD8. In this way both immune activation and anti-tumour activity could be monitored. Conjugate formation between tumour cells and activated lymphocytes was seen as soon as 4 h after injection of BIS-1-redirected activated lymphocytes, followed by a disappearance or reduction of tumour cells after 24–48 h. In parallel with this, the soluble tumour marker CEA decreased in the effusion fluid following injection with the BIS-1-redirected lymphocytes. Furthermore, a steep increase in local granulocyte numbers was observed in the effusion fluid, which reached a maximum 24–48 h after the start of the treatment. Also levels of IL-6 and TNF were greatly elevated. The data suggest tha the treatment induces both antitumour activity and a strong local inflammatory reaction. This is accompanied by no or only minor local and systemic toxicity, i.e. mild fever, which disappeared as the local inflammatory reaction diminished 48–72 h after treatment.Type of Medium: Electronic ResourceURL: -
6Articles: DFG German National LicensesStaff View
ISSN: 1432-0584Keywords: Paroxysmal nocturnal haemoglobinuria-vascular complicationsSource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Summary Two patients with paroxysmal nocturnal haemoglobinuria (PNH) are described who had severe vascular complications. The first patient developed extensive thrombosis of the abdominal veins leading to intractable ascites symptomatically treated with a peritoneo-venous shunt. The second patient had aneurysm of the abdominal aorta treated with a prosthetic graft. Although in both patients prosthetic grafts were implanted no signs of an increased activation of the P.N.H. cells were found and no thrombosis or severe haemolytic anaemia occurred. It is suggested that surgical intervention for vascular complications in PNH should not be delayed because of fear of activating the PNH.Type of Medium: Electronic ResourceURL: -
7Articles: DFG German National LicensesStaff View
ISSN: 1432-0584Keywords: Acute lymphocytic leukaemia ; Adults ; Chemotherapy ; CNS prophylaxisSource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Summary Twenty-five consecutive adult patients with acute lymphocytic leukaemia (ALL) all achieved complete remission, twenty-two with vincristine-prednisone, while thirteen patients also received daunorubicin (DNR). Three patients obtained remission only after treatment with cytosine arabinoside (Ara-C), 6 thioguanine (6-TG) and adriamycin (ADM). Despite central nervous system (CNS) prophylaxis by intraventricular injections via an Ommaya reservoir, 2/22 patients had a CNS relapse. The median remission duration of the whole group was 19 months. Four patients could stop therapy after 3 years. The median survival duration of all patients was 38 months. The quality of life of the patients during this chemotherapeutic regimen was good.Type of Medium: Electronic ResourceURL: -
8Articles: DFG German National LicensesImhoff, G. W. ; Arnaud, F. ; Postmus, P. E. ; Mulder, N. H. ; Das, P. C. ; Smit Sibinga, C.Th.
Springer
Published 1983Staff ViewISSN: 1432-0584Keywords: Cryopreserved autologous platelets ; Autologous bone marrow transplantationSource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Summary Autologous platelets were harvested and cryopreserved in eight consecutive patients elected for ablative chemotherapy and autologous bone marrow transplantation (ABMT) for solid malignancy. There was a 19% loss in platelet count after the freeze thaw and wash procedure; with an in vitro functional loss of 40–60%. No correlation could be found for individual platelet transfusions between in vitro functional tests and in vivo recovery. Six consecutive patients received a total of 16 autologous platelet transfusions in the aplastic phase of ABMT. No bleeding was observed during the study period and there was no CMV infection in the recipients. While improvement in freezing and subsequent handling is desirable, autologous cryopreserved platelets can safely be used for the prophylaxis of bleeding during aplasia in patients treated with ABMT.Type of Medium: Electronic ResourceURL: -
9Articles: DFG German National LicensesStaff View
ISSN: 1432-0584Keywords: aplastische Anämie ; prognostische Systeme ; Aplastic anaemia ; Prognostic systemsSource: Springer Online Journal Archives 1860-2000Topics: MedicineDescription / Table of Contents: Summary In 43 patients with aplastic anaemia we assessed the accuracy of different prognostic systems. Patients dying within 6 months after diagnosis were correctly predicted in 60% of cases with the Lynch-index with a sensitivity of 82%. With the Najean-index 40% of these patients are correctly predicted, this index has a sensitivity of 100%. More accurate are the prognostic criteria proposed by Camitta et al [5]. With these criteria, this rapidly fatal group is correctly predicted in 85% of the patients, indicating that 15% Of the patients are incorrectly predicted to have a limited survival. The sensitivity, however, is 100%. The Lohrmann-index, based on reticulocyte count predicts 64% of this group with severe aplasia. None of these prognostic systems do accurately predict long survival. We suggest that the best differentiation between patients with a long-term prognosis (more than 5 years) and patients who die from aplastic anaemia within 5 years, is made by re-evaluating the leucocyte and platelet count 3 months after the initial diagnosis. Decrease in blood counts (over 10%) predicts death from aplastic anaemia within 5 years correctly in all patients; stable or increased blood counts predict long survival in 75% of the patients.Notes: Zusammenfassung In Hinblick auf die Prognose wurde an 43 Patienten mit aplastischer Anämie die Zuverlässigkeit einiger Untersuchungsmethoden geprüft. Mit Hilfe des Lynch-Index konnte bei 60% der Patienten, die innerhalb von 6 Monaten nach Abklärung der Diagnose starben, eine richtige Prognose gestellt werden; die Sensitivität war hierbei 82%. Mit dem Najean-Index konnte bei 40% dieser Patienten eine richtige Prognose gestellt werden; dieser Index ergab eine Sensitivität von 100%. Die prognostischen Kriteria, von Camitta et al. [5] vorgeschlagen, ergaben ein besseres Resultat: Bei 85% der Patienten mit diesen Kriteria war die Prognose richtig, d.h., in 15% der Fälle wurde zu Unrecht eine kürzere Lebensdauer vermutet; dies bei einer Sensitivität von 100%. Der Lohrmann-Index, welcher sich auf die Retikulozytenanzahl als Gradmesser für die Prognose bezieht, ergab in dieser Serie eine Spezifität von 64%. Keine dieser Untersuchungsmethoden ermöglichte es, bei Patienten mit einer längeren Lebensdauer eine richtige Prognose zu stellen. Bei dieser Patientengruppe erlaubt die Bestimmung der Leukozyten und Thrombozyten 3 Monate nach Abklärung der Diagnose es, Patienten mit längerer (über 5 Jahren) und kürzerer Lebensdauer (unterhalb von 5 Jahren) prognostisch voneinander zu unterscheiden. Eine gleichzeitige Abnahme der Leukozyten und Thrombozyten (〉 10%) bedeutete bei allen Patienten Tod innerhalb von 5 Jahren; Gleichbleiben oder Zunahme hingegen bei 75% der Patienten eine längere Lebensdauer.Type of Medium: Electronic ResourceURL: -
10Articles: DFG German National LicensesVries, E. G. E. ; Vriesendorp, R. ; Meinesz, A. F. ; Mulder, N. H. ; Postmus, P. E. ; Th. Sleijfer, D.
Springer
Published 1984Staff ViewISSN: 1432-0584Keywords: Bone marrow transplantation ; Local anesthesiaSource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Summary A prospective study with mild general analgesia and sedation together with local anesthesia during bone marrow harvest was performed. Thirty-one patients underwent 33 bone marrow collections. Pretreatment consisted of 100 mg meperidine i.m. and 20 mg diazepam i.m. 1 h before start of procedure. Eight patients got additional meperidine and diazepam during the procedure, all patients got lidocaine 1% locally. A mean volume of 1.321 was obtained with 42.5 punctures. Twenty-two patients had no complications, 4 vomited, 4 had easily correctable hypotension of short duration, one got oxygen for cyanosis of short duration. Acceptance was good in 23 patients, in 6 reasonably well, in two bad. Only one patient experienced pain problems, due to suction. Anxiety was no major problem due to good information before the procedure and mild sedation. This form of anesthesia for bone marrow collection is a safe procedure, it is generally well accepted by the patient and it can be performed on an out-patient basis.Type of Medium: Electronic ResourceURL: -
11Articles: DFG German National LicensesMeijer, S. ; Mulder, N. H. ; Sleijfer, D. Th. ; Jong, P. E. ; Sluiter, W. J. ; Schraffordt Koops, H. ; Hem, G. K.
Springer
Published 1982Staff ViewISSN: 1432-0843Source: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Summary We studied renal function in nine patients with disseminated testicular carcinoma before and after remission-induction and maintenance therapy with a drug combination containing cis-platinum. The median glomerular filtration rate (GFR) decreased during remission-induction therapy from 146 to 118 ml/min. No effect of cumulative toxicity on the median GFR was found during maintenance therapy, nor did the median GFR improve. The median effective renal plasma flow (ERPF) decreased during the total period from 705 to 514 ml/min. No significant changes in median filtration fraction (FF) and serum creatinine were observed. It is suggested that intrarenal hemodynamic effects are important in the nephrotoxicity of cis-diamminedichloride platinum (CDDP).Type of Medium: Electronic ResourceURL: -
12Articles: DFG German National LicensesKroesen, B. J. ; Nieken, J. ; Sleijfer, D. T. ; Molema, G. ; de Vries, E. G. E. ; Groen, H. J. M. ; Helfrich, W. ; The, T. H. ; Mulder, N. H. ; de Leij, L.
Springer
Published 1997Staff ViewISSN: 1432-0851Keywords: Key words Lung cancer ; CD3×EGP-2 ; Bispecific monoclonal antibodySource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Abstract The bispecific monoclonal antibody (bsAb) BIS-1 combines a monoclonal-antibody(mAb)-defined specificity for the CD3 complex, as present on all T lymphocytes, with a mAb-defined specificity for the pancarcinoma/epithelium associated glycoprotein EGP-2. In vitro studies indicate that BIS-1 can direct T lymphocytes to kill EGP-2-positive tumour target cells. T cell pre-activation is necessary for this activity and can be obtained either via incubation of isolated peripheral blood mononuclear cells with CD3 mAb, followed by short culturing in recombinant interleukin-2-containing medium, or via costimulation with CD5- and CD28-based bsAb. Clinical application of BIS-1 was started in a pilot study in which carcinoma patients suffering from malignant ascites or intrapleural effusion were treated. In this study, ex vivo activated autologous lymphocytes were applied locally, i.e. intraperitoneally or intrapleurally, in the presence of BIS-1. Local inflammation and antitumour activity were observed, whereas no or only minor systemic toxicity was seen in these patients. Intravenous administration of BIS-1 F(ab′)2 in combination with subcutaneously given recombinant interleukin-2 (i.v. bsAb/rIL-2 treatment) induced transient but considerable toxicity including peripheral vasoconstriction, dyspnoea and fever with a maximal tolerated dose of 5–8 μg/kg. High plasma concentrations of the inflammatory cytokines tumor necrosis factor α and interferon γ were observed at this dose. Whereas bsAb-dictated antitumour activity could be demonstrated to be present in blood samples of these patients in an in vitro assay, no clear clinical responses were observed. In a rat model it was found that i.v. bsAb/rIL-2 treatment of EGP-2-positive tumours was effective when a low systemic tumour burden was present, suggesting that systemic bsAb/rIL-2 treatment might be effective in situations of minimal residual disease.Type of Medium: Electronic ResourceURL: -
13Articles: DFG German National LicensesStaff View
ISSN: 1432-1335Keywords: Lung cancer ; VindesineSource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Summary Vindesine 1.75 mg/m2, twice weekly for 2 weeks followed by 2 weeks rest, was given to 26 lung cancer patients. In 6 patients a partial response was seen (23%). Neurotoxicity was present in 15 patients after 1 course; in 6 patients this was the reason for stopping therapy. This regimen has no advantage over weekly vindesine.Type of Medium: Electronic ResourceURL: -
14Articles: DFG German National LicensesMulder, N. H. ; Sleijfer, D. Th. ; Vries, E. G. E. ; Koops, H. Schraffordt ; Samson, M. J. ; Willemse, P. H. B.
Springer
Published 1989Staff ViewISSN: 1432-1335Keywords: Malignant melanoma ; ChemotherapySource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Summary Thirty-one patients with disseminated malignant melanoma were treated with a combination chemotherapy of bleomycin, dacarbazine and vindesine. Five complete responses, and five partial remissions occurred. One patient survived for over 2 years without evidence of disease. This combination of drugs may give better results, as far as complete recovery and long-term survival are concerned, than single-agent therapy with dacarbazine.Type of Medium: Electronic ResourceURL: -
15Articles: DFG German National LicensesMulder, N. H. ; Sleijfer, D. Th. ; Vries, E. G. E. ; Koops, H. Schraffordt ; Willemse, P. H. B.
Springer
Published 1990Staff ViewISSN: 1432-1335Keywords: Malignant melanoma ; ChemotherapySource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Summary Twenty-one patients with disseminated malignant melanoma were treated with a combination of carboplatin and cytosine arabinoside. Two complete and three partial remissions occurred. No complete cross-resistance was found with a regimen containing 5-(dimethyltriazeno)imidazole-4-carboxamide (DTIC) in two patients. It is suggested that this regimen might be studied further as a second-line treatment for patients who fail on DTIC-containing treatment.Type of Medium: Electronic ResourceURL: -
16Articles: DFG German National LicensesStaff View
ISSN: 1569-8041Keywords: adjuvant treatment ; Dukes' C colon cancer ; 5-fluorouracil ; leucovorin ; levamisoleSource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Abstract Purpose:To assess the effect of the addition of leucovorin to thecombination of 5-fluorouracil (5-FU)–levamisole on recurrence risk andoverall survival in patients after a resection with curative intent of aDukes' C colon cancer. Patients and methods:Five hundred patients with Dukes' C coloncancer were randomly assigned to adjuvant treatment for one year with5-fluorouracil (450 mg/m2 i.v. weekly) and levamisole (150 mg p.o.every two weeks), the C-group or with leucovorin (20 mg/m2 i.v.),5-fluorouracil and levamisole, the L-group. The median follow-up for patientsstill alive is 36 months. Four patients were ineligible because of advanceddisease at the time of randomisation. Results:Sixty percent of the patients have completed all coursesof chemotherapy. Of the remaining 40% of the patients who did notcomplete one-year treatment with chemotherapy, 46% discontinued becauseof toxic and/or emotional reasons. They were equally divided over bothtreatment arms. The addition of leucovorin increased toxicity (especiallymucositis and conjunctivitis) without a significant increase in treatmentwithdrawal. Five-year disease-free interval (C-group: 49%, L-group:46%; log-rank test, P = 0.86) and overall survival (C-group:55%, L-group: 59%, log-rank test: P = 0.96) were verysimilar in both treatment arms. Conclusions:The addition of low dose leucovorin to thecombination of 5-fluorouracil and levamisole in a 12-month adjuvant therapyfor curatively resected Dukes' C colon cancer patients does not improvedisease-free interval nor overall survival. The addition of leucovorin to thecombination of 5-FU–levamisole increases toxicity. Thereforeleucovorin–5-FU–levamisole is not recommended in a 12 monthsadjuvant regime of Dukes' C colon cancer.Type of Medium: Electronic ResourceURL: -
17Articles: DFG German National LicensesStaff View
ISSN: 1439-0973Source: Springer Online Journal Archives 1860-2000Topics: MedicineDescription / Table of Contents: Zusammenfassung In einer retrospektiven Analyse wurde der Wert von Amphotericin B Lutschtabletten zur selektiven Elimination von Hefen aus dem Oropharynx geprüft. Die Untersuchungen wurden an vier verschiedenen Gruppen von Patienten mit hochgradiger Granulozytopenie durchgeführt. Amphotericin B wurde allen 77 Patienten oral als Suspension oder Tabletten verabreicht. Zusätzlich wurden täglich vier Amphotericin B Lutschtabletten zur lokalen Pilz-Dekontamination des Oropharynx gegeben und zwar bei Vorliegen von Faktoren, die die Kolonisationsresistenz verminderten, wie Nasensonden (Gruppe I, 19 Patienten) oder Schleimhautdefekt (Gruppe III, 25 Patienten) und bei Patienten, bei denen bereits viermal oder öfter Hefen in Rachenabstrichen nachgewiesen worden waren (Gruppe IV, 11 Patienten). Die 22 Patienten von Gruppe II erhielten keine Lutschtabletten. Die zusätzliche topische Behandlung mit Lutschtabletten führte zu einer Verminderung der mittleren „Wachstumsdichte“ vonCandida Zellen im Oropharynx. Diese Keimreduktion war signifikant in Gruppe III (p 〈 0.01) und in Gruppe IV (p 〈 0.02); sie stellte sich während der ersten Behandlungswoche ein. Bei Patienten mit Nasensonden wurden in 51,8% der Rachenabstriche Hefen gezüchtet. Möglicherweise könnte bei diesen Patienten eine Dosiserhöhung die Ergebnisse verbessern. Bei Patienten, die fürCandida-infektionen empfänglich sind, wird die topische Behandlung des Oropharynx mit Amphotericin B Lutschtabletten empfohlen.Notes: Summary A retrospective evaluation was made on the value of amphotericin B lozenges in the selective elimination of yeasts from the oropharynx. Four different groups of severely granulocytopenic patients were studied. All 77 patients received amphotericin B orally as a suspension or as tablets. Four amphotericin B lozenges were also administered daily for topical antimycotic decontamination of the oropharynx. This was done in the presence of colonization-resistance decreasing factors such as a nasogastric tube (Group I, 19 patients) or mucosal damage (Group III, 25 patients) and in patients with four or more consecutive throat swab cultures with yeasts (Group IV, 11 patients). The 22 patients in Group II did not receive lozenges. The addition of lozenges resulted in a decrease in the mean “growth density” ofCandida cells in the oropharynx. This reduction was significant in Group III (p 〈 0.01) and Group IV (p 〈 0.02) and became evident during the first week of treatment. In patients with a nasogastric tube, however, 51.8% of the throat swab cultures revealed yeasts. Increasing the dose of the lozenges might improve the results in these patients. Topical treatment of the oropharynx with amphotericin B lozenges is advocated for patients who are susceptible toCandida infections.Type of Medium: Electronic ResourceURL: -
18Articles: DFG German National LicensesVellenga, E. ; Mulder, N. H. ; Zanten, A. K. ; Nieweg, H. O. ; Woldring, M. G.
Springer
Published 1983Staff ViewISSN: 1619-7089Source: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Abstract The level of the aminoterminal propeptide Col 1–3 of type III procollagen (PC-III) was determined in patients with paroxysmal nocturnal haemoglobinuria (PNH) and primary myelofibrosis (PMF), to study whether PC-III can be used as a parameter for the rate and/or degree of bone marrow replacement with collagen. Normal PC-III levels were found in PNH (6.6±1.1 μg/l; N: 8.6±1.8 μg/l), while significantly increased levels were found in PMF (24.8±2.2 μg/l). During a follow-up of 1 year, a slight increase of 2 μg/l occurred in three patients with a stable fibrosis, while one patient with more active disease demonstrated an increase of 25 μg/l. Treatment with acetylsalicylic acid led to a decline of PC-III as well as β-thromboglobulin level, although normalization did not occur. It was demonstrated by means of gel filtration that the antigens related to the PC-III peptide were heterogenous, and that in PMF at least two main peaks were present, with molecular masses equal to and smaller than PC-III peptide. These data demonstrate that the radioimmunoassay cannot be used for the quantitative determination of PC-III; nevertheless it gives some insight in the process of bone marrow fibrosis.Type of Medium: Electronic ResourceURL: -
19Articles: DFG German National LicensesSmit, J. M. ; Jurjens, H. ; Bouman, J. ; Bijzet, J. ; Sleijfer, D. Th. ; Woldring, M. G. ; Mulder, N. H.
Springer
Published 1985Staff ViewISSN: 1619-7089Keywords: Polyamine ; Spermidine ; Malignant melanoma ; PolychemotherapieSource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Abstract Before, during, and after 19 courses of chemotherapy given to patients with disseminated malignant melanoma plasma spermidine levels were determined with a radioimmunoassay. Baseline values were normal in 17 courses, a doubling of plasma levels following chemotherapy occurred in 13 courses. There was no relation between the occurrence of a tumor response and an increase in spermidine levels nor between hematological toxicity or digestive tract toxicity and spermidine levels.Type of Medium: Electronic ResourceURL: -
20Articles: DFG German National LicensesVries, E. G. E. ; Rodenhuis, S. ; Schouten, H. C. ; Hupperets, P. S. G. J. ; Dolsma, W. V. ; Lebesque, J. V. ; Blijham, G. H. ; Bontenbal, M. ; Mulder, N. H.
Springer
Published 1996Staff ViewISSN: 1573-7217Keywords: high-dose chemotherapy ; metastatic breast cancerSource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Summary Background This trial studied the disease-free survival after high-dose chemotherapy in patients in complete remission of metastatic breast cancer. Patients and methods Thirty women, mean age 42.2 years (range 33–55) with metastatic breast cancer, received high-dose chemotherapy in a phase II study. Patients were eligible if they were ≤ 55 years of age, had achieved complete remission within 6 months of the initiation of chemotherapy, and had a WHO performance scale of 0 or 1. The high-dose regimen consisted of melphalan 180 mg/m2 and mitoxantrone 60 mg/m2 both divided over 3 days. On day 7 bone marrow and/or peripheral stem cells were infused. After bone marrow recovery, external beam radiation was administered to sites of previous metastatic disease in 15 patients. Results Apart from leuko- and thrombocytopenia, mucositis was the major side effect. One patient died during the bone marrow transplant period due to an aspergillus infection. The median follow-up since highdose chemotherapy is 25 months (range 13 to 56 months). The median disease-free survival since high-dose chemotherapy is 27 months and the disease free survival is still 43% with an overall survival of 53% at 3 years. In two patients tumor relapse occurred only in the brain; in one patient the only relapse sign was a meningeal carcinosis. At the moment 17 patients are disease-free (13+–56+) months after high-dose chemotherapy. Conclusion Until now this high-dose regimen in selected patients with complete remission after induction chemotherapy for metastatic breast cancer has a promising disease free survival.Type of Medium: Electronic ResourceURL: